📊Case Study: PLTR, AMAT & CVS

Dive deep into Market Cycle and Portfolio updates, and catch daily market highlights. Plus, don't miss our case study featuring PLTR, AMAT and CVS

#Market Cycle and Portfolio Updates

📆23-08-17

Click here for access the Market Cycle and Alfa Hedge Portfolio II Update

#keypoints

• Market Highlights:

  • US Stocks Drop, Economy Strong

• 📊Case Study

  • PLTR 0.00%↑ : AI Stock Billionaires are Selling

  • AMAT 0.00%↑ : Optimistic Forecast Amidst Easing Chip Slump

  • CVS 0.00%↑ : Significant drop

---

Market Highlights

• US Stocks Drop, Economy Strong

  • Major Indices Performance:

    • The Dow Jones decreased by 0.8%.

    • The S&P 500 also dropped by approximately 0.8%.

    • The tech-focused Nasdaq Composite declined by more than 1% for the third straight day.

• 10-Year US Treasury Yield:

  • Settled just under 4.3%, which is close to recent high levels.

  • Globally, yields are at levels not witnessed since the Great Recession.

• Economic Data:

  • Weekly unemployment claims showed a decrease, signaling sustained strength in the job market.

---

📈Market Cycle Analysis PLTR 0.00%↑ AMAT 0.00%↑ CVS 0.00%↑

The Alfa Hedge Data Analysis was developed by Zurique Capital, to identify the Markets Cycles (through ETFs) combining:

1. Market Cycle Phase, with this data we analyze the present situation of the Market.

2. Historical positive volatility (highest probability of Long-Term uptrends), with this data we analyze the past.

3. Reward/Risk Ratio and Expectancy Ratio, with this data we analyze what to expect in the future based on statistics (not astrology or opinions).

The Alfa Hedge Portfolio don't invest in stocks directly, but through indexes ETFs, so, the weight shown in the image is based on the weight of the stock on the index and the weight of this index in the Alfa Hedge Portfolio.

This analysis are not investment recommendations and investors must do their own research (please read the Disclaimer section).

We invest our own money and share our Portfolio with Premium Subscribers.

Premium Subscribers have full access to our Alfa Hedge Portfolio II in a Real-Life Brokerage Account in Real Time.

Know More About Premium Subscription

PLTR 0.00%↑ : AI Stock Billionaires are Selling

• Five billionaires sold large portions of Palantir stock.

  • Ken Griffin (Citadel Advisors)

  • Philippe Laffont (Coatue Management)

  • Israel Englander (Millennium Management)

  • Jim Simons (Renaissance Technologies)

  • Jeff Yass (Susquehanna International)

• Reasons for the sell-off:

  • Palantir's high valuation given the expected revenue growth.

  • Despite the high valuation, Palantir's unique operating model and cash-flow predictability give it a premium value.

📈ALFA HEDGE ANALYSIS PLTR 0.00%↑

🟢Market Cycle Phase: Positive Cycle

🟠Alfa Hedge Portfolio II: Not represented through S&P, Dow Jones or Nasdaq

🟢Historical positive volatility: Average Return Positive

🟢Reward/Risk Ratio: >2

🟢Expectancy Ratio: >0

📈ALFA HEDGE ANALYSIS PLTR

AMAT 0.00%↑ : Optimistic Forecast Amidst Easing Chip Slump

• Company Profile: Applied Materials, top U.S. chipmaking machinery manufacturer.

• Q4 Sales Projection: Predicts strong Q4 sales of $6.51 billion.

• Main Drivers: Growth in artificial intelligence and internet-connected devices.

• Challenges: Oversupplied market and reduced memory chip demand.

• Optimism: Confident in broader semiconductor adoption across industries.

📈ALFA HEDGE ANALYSIS AMAT 0.00%↑

🟢Market Cycle Phase: Positive Cycle

🟠Alfa Hedge Portfolio II: Represented through S&P, Dow Jones or Nasdaq

🟢Historical positive volatility: Average Return Positive

🟢Reward/Risk Ratio: >2

🟢Expectancy Ratio: >0

📈ALFA HEDGE ANALYSIS AMAT

CVS 0.00%↑ : Significant drop

• CVS (CVS) experienced a significant drop.

• This was influenced by a report suggesting that the insurer, Blue Shield of California, intends to reduce its dependence on CVS for pharmacy services.

• Instead, they are considering a shift towards Amazon and Mark Cuban's drug firm. Consequently, CVS stock plummeted by more than 8%.

📈ALFA HEDGE ANALYSIS CVS 0.00%↑

🔴Market Cycle Phase: Negative Cycle

🟠Alfa Hedge Portfolio II: Represented through S&P, Dow Jones or Nasdaq

🟢Historical positive volatility: Average Return Positive

🟢Reward/Risk Ratio: >2

🟢Expectancy Ratio: >0

📈ALFA HEDGE ANALYSIS CVS

Before buy PLTR 0.00%↑, AMAT 0.00%↑ or CVS 0.00%↑ see inside our Portfolio in Real Time

Become a Premium Subscriber and get full access to our Alfa Hedge Portfolio II in real time.

Every business day we update the evolution of the Alfa Hedge Portfolio II.

Premium Subscribers have full access to our Alfa Hedge Portfolio II in a Real-Life Brokerage Account in Real Time.

---

If you liked this content, you will love our Report.👇

Wall Street Insider Report

Demystify the MARKET CYCLES investing SMARTER in Wall Street

Theory + Action: Learn & Replicate a High Performance + Low Maintenance + Long-Term Portfolio

Join +13k Global Investors and Really Master the Market Cycle Investing

---

Disclaimer:

The publisher does not guarantee the accuracy or completeness of the information provided in this page.

All statements and expressions herein are the sole opinion of the author.

The Zurique Capital is a publisher of financial information, not an investment advisor.

We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.

THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME.

THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION.

INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN.

No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.

Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable.

They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur.

Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein.

The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.

The publisher, its affiliates, and clients of the a publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities).

To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.

Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.

By using the Site or any affiliated social media account, you are indicating your consent and agreement to this disclaimer and our terms of use.

Unauthorized reproduction of this newsletter or its contents by photocopy, facsimile or any other means is illegal and punishable by law.

For Full Terms of Use Click HERE. For the Privacy Policy Click HERE.

wallstreetinsiderreport.com (“Zurique Capital”) is a website owned and operated by Substack.

By accessing this website or any page thereof, you agree to be bound by the Terms of Use and Privacy Policy, in effect at the time you access this website or any page thereof.

The Terms of Use and Privacy Policy may be amended from time to time. Nothing on this website shall constitute an offer to sell, or a solicitation of an offer to buy or subscribe for, any securities to any person in any jurisdiction where such an offer or solicitation is against the law or to anyone to whom it is unlawful to make such offer or solicitation.

“Zurique Capital” is not an underwriter, broker-dealer, Title III crowdfunding portal or a valuation service and does not engage in any activities requiring any such registration.

“Zurique Capital” does not provide advice on investments or structure transactions.

Offerings made under Regulation A under the U.S. Securities Act of 1933, as amended (the "Securities Act") are available to U.S. investors who are “accredited investors” as defined by Rule 501 of Regulation D under the Securities Act well as non-accredited investors, who are subject to certain investment limitations as set forth in Regulation A under the Securities Act.

In order to invest in Regulation A offerings, investors may be asked to fill out a certification and provide necessary documentation as proof of your income and/or net worth to verify that you are qualified to invest in offerings posted on this website.

All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities.

“Zurique Capital” does not verify the adequacy, accuracy or completeness of any information.

Neither “Zurique Capital” nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, valuations of securities or completeness of any information on this site or the use of information on this site.

Neither “Zurique Capital” nor any of its directors, officers, employees, representatives, affiliates or agents shall have any liability whatsoever arising from any error or incompleteness of fact, or lack of care in the preparation of, any of the materials posted on this website.

Investing in securities, especially those issued by start-up companies, involves substantial risk. investors should be able to bear the loss of their entire investment and should make their own determination of whether or not to make any investment based on their own independent evaluation and analysis.